Dechra Pharmaceuticals (DPH)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 15.7 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 3.90 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Jun | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Last ex-div: 13th Mar, paid: 9th Apr more... Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | +27.7% | |||||||||
FINANCIAL BRIEF: For the six months ended 31 December 2012, Dechra Pharmaceuticals plc revenues increased 20% to L252.2M. Net income increased 28% to L8.6M. Revenues reflect European Pharmaceuticals segment increase of 82% to L74.8M, Services segment increase of 5% to L167.4M, US Pharmaceuticals segment increase of 9% to L10M. Net income benefited from European Pharmaceuticals segment income increase of 66% to L21.2M. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 4 | 2 | 0 |
Dechra Pharmaceuticals PLC (Dechra) is a holding company. The Company operates in four segments: Product Development, European Pharmaceuticals, US Pharmaceuticals and Services. European Pharmaceuticals markets and sells pharmaceuticals and specialist pet foods to the veterinary profession in Europe. It comprises Dechra Veterinary Products Europe and Dechra manufacturing. US Pharmaceuticals markets and sells a range of endocrine, ophthalmic, dermatological and equine products into North America. It includes Dechra Veterinary Products US. Services segment distributes veterinary products, including pharmaceuticals, specialist pet diets and instruments to veterinary practices within the United Kingdom. It also provides histology, pathology, haematology, chemistry and microbiology services to veterinary practices. In January 2012, Dechra acquired rights to HY-50. In May 2012, it acquired Eurovet Animal Health B.V.
Directors: Ian Page (CEO) 51, Anne-Francoise Nesmes (CFO) , Mike Eldred (Corp. Exec.) , Tony Griffin (Mgng.Dir.) , Mike Annice (Mgng.Dir.) , Peter Graham (Mgng.Dir.) 44, Martin Riley (Mgng.Dir.) , Paul Sandland (Contr.) , Ed Torr (Exec. Dir.) 52, Barbara Johnson (Dir.-HR) ,
No. of Employees: 1,042 No. of Shareholders: n/a
| Last Annual | June 30th, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 87,072,727 |
| Free Float | 82.8m (95.1%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE 350 Act , FTSE Lower Yield , FTSE 250 Mid , FT350 Phar & Bio , |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | Dechra House,Jamage Industrial Estate Talke Pits, Talke Pits, STOKE-ON-TRENT, ST7 1XW, United Kingdom |
| Web | http://www.dechra.com |
| Phone | +44 1782 771100 |
| Contact | Zoe Bamford (Secy.,) |
| Registrar | Computershare Investor Services PLC (Bristol) |
| Auditors | KPMG Audit PLC |
| 8th May | Interim Management Statement |
| 1st May | Total Voting Rights |
| 22nd Apr | Holding(s) in Company |
| 15th Apr | Change of Registered Office |
| 28th Mar | Total Voting Rights |
| 15th Mar | Blocklisting Six Monthly Return |
Recent ↓
